Page 64 - Vitamin D and Cancer

2 The Molecular Cancer Biology of the VDR 51

171. Shah S et al (2006) The molecular basis of vitamin D receptor and beta-catenin crossregula-
tion. Mol Cell 21:799–809
172. Miller CW, Morosetti R, Campbell MJ, Mendoza S, Koeffler HP (1997) Integrity of the 1,
25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers. Mol Carcinog
19:254–257
173. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Colston KW (2003) Approaches to evaluat-
ing the association of vitamin D receptor gene polymorphisms with breast cancer risk.
Recent Results Cancer Res 164:43–54
174. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA (2005) Sun exposure, vitamin D
receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res
65:5470–5479
175. Ingles SA et al (1998) Association of prostate cancer with vitamin D receptor haplotypes in
African-Americans. Cancer Res 58:1620–1623
176. Ma J et al (1998) Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk
of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7:385–390
177. Gorlach M, Burd CG, Dreyfuss G (1994) The mRNA poly(A)-binding protein: localization,
abundance, and RNA-binding specificity. Exp Cell Res 211:400–407
178. Kim JG et al (2003) Association between vitamin D receptor gene haplotypes and bone mass
in postmenopausal Korean women. Am J Obstet Gynecol 189:1234–1240
179. Kuraishi T, Sun Y, Aoki F, Imakawa K, Sakai S (2000) The poly(A) tail length of casein
mRNA in the lactating mammary gland changes depending upon the accumulation and
removal of milk. Biochem J 347:579–583
180. Schondorf T et al (2003) Association of the vitamin D receptor genotype with bone metas-
tases in breast cancer patients. Oncology 64:154–159
181. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S (1999)
Association of breast cancer progression with a vitamin D receptor gene polymorphism.
South-East Sweden Breast Cancer Group. Cancer Res 59:2332–2334
182. Guy M et al (2004) Vitamin d receptor gene polymorphisms and breast cancer risk. Clin
Cancer Res 10:5472–5481
183. Ntais C, Polycarpou A, Ioannidis JP (2003) Vitamin D receptor gene polymorphisms and
risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12:1395–1402
184. Rashid SF et al (2001) Synergistic growth inhibition of prostate cancer cells by 1 alpha, 25
Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either
sodium butyrate or trichostatin A. Oncogene 20:1860–1872
185. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP (2000) The anti-proliferative
effects of 1alpha, 25(OH)2D3 on breast and prostate cancer cells are associated with induc-
tion of BRCA1 gene expression. Oncogene 19:5091–5097
186. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA (1995) Vitamin D receptor expression,
24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in
seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997–1003
187. Rashid SF, Mountford JC, Gombart AF, Campbell MJ (2001) 1alpha, 25-dihydroxyvitamin D(3)
displays divergent growth effects in both normal and malignant cells. Steroids 66:433–440
188. Campbell MJ, Adorini L (2006) The vitamin D receptor as a therapeutic target. Expert Opin
Ther Targets 10:735–748
189. Battaglia S, Maguire O, Thorne JL, Hornung LB, Doig CL, Liu S, Sucheston LE, Bianchi A,
Khanim F, Gommersall LM, Coulter HS, Rakha S, Giddings I, O’Neill LP, Cooper CS,
McCabe CJ, Bunce CM, Campbell MJ (2010) Elevated NCOR1 disrupts PPAR{alpha}/
{gamma} signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis
31(9):1650–60
190. Kim JY, Son YL, Lee YC (2008) Involvement of SMRT Corepressor in Transcriptional
Repression by the Vitamin D Receptor. Mol Endocrinol 23(2):251–64
191. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF (2007) Increased expression of
corepressors in aggressive androgen-independent prostate cancer cells results in loss of
1alpha, 25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 5:967–980